Gothenburg, Sweden – 21 October 2024 – Following the regulatory approval and launch of the world’s first commercial module for manufacturing of Astatine-211 (At-211) radiopharmaceuticals, Atley Solutions has delivered and installed the first commercial unit at Minerva Imaging’s facilities in Denmark. The delivery of the Atley C100 marks a significant technical and commercial milestone for Atley Solutions and strengthens the company’s position as a global leader in commercial products and services for At-211 radiopharmaceuticals. Further, it strengthens both companies’ ability to offer research, development and manufacturing services.
Atley and Minerva’s collaboration to enable the discovery, preclinical evaluation, and early clinical development of novel At-211 radiopharmaceuticals was first announced in January 2024.
“We are excited to be able to complete the first installation of a commercial Atley C100 module at our partner Minervia Imaging. We have chosen a great site and partner for this first installation, since it will enable both more preclinical studies with novel At-211 radiopharmaceuticals, and the supply of clinical radiopharmaceutical doses.” said Milton Lönnroth, CEO of Atley Solutions.
At-211 radiopharmaceuticals – the next frontier in cancer treatment
Targeted radionuclide therapy is a precision medicine that uses radioactive substances attached to targeting moieties to specifically attack cancer cells. By labeling drugs with radioactive isotopes, radiation can be precisely delivered to cancer cells, reducing side effects compared to traditional therapies. Recently, targeted radionuclide therapies have grown significantly. At-211, with its short half-life, favorable decay chain, and scalable production, has unique properties as a payload for these radiopharmaceuticals.
One Integrated Platform for Purifying At-211 and Synthesizing At-211 radiopharmaceuticals
The Atley C100 module can both purify At-211 from irradiated cyclotron targets and synthesize At-211-based radiopharmaceuticals in an automated process. As a platform technology, the Atley C100 can be used to develop and manufacture multiple different At-211 radiopharmaceuticals. With its recent CE marking and CB certification, the Atley C100 is now available to researchers and drug developers worldwide, offering new possibilities in the field of targeted cancer therapy.
The Atley C100 addresses some of the key obstacles in At-211 radiopharmaceutical development, a field that has long faced constraints due to the lack of specialised manufacturing tools. By providing a platform for manufacturing these compounds, the module helps to connect scientific research with clinical application.
Minerva Imaging – a fully integrated CRO and CDMO specialized in targeted radionuclide therapies.
Built on more than two decades of research in Nuclear Medicine, Minerva focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services.
“At-211 holds strong promises as a payload for targeted radionuclide therapy, contributing to the development of medicines for patients with an unmet need. With the installation of the commercial version of the Atley C100 module, Minerva Imaging has all the capabilities in-house to support our collaborators in studies utilizing At-211, from preclinical target validation to early clinical work. We are excited to continue our collaboration with Atley on making At-211 available for preclinical and clinical translation” said Carsten H. Nielsen, co-founder and CEO of Minerva Imaging.
